Navigation Links
China Medicine Announces Solid First Quarter 2008 Results
Date:5/12/2008

GROSS PROFIT 2,312,020 1,687,578

OPERATING EXPENSES

Research and development 88,392 100,112

Selling, general and administrative 812,508 643,846

Total operating expenses 900,900 743,958

INCOME FROM OPERATIONS 1,411,120 943,620

OTHER INCOME (EXPENSE), NET 5,983 (2,972)

INCOME BEFORE INCOME TAXES 1,417,103 940,648

AND MINORITY INTEREST

PROVISION FOR INCOME TAXES 268,767 199,959

INCOME BEFORE MINORITY INTEREST 1,148,336 740,689

MINORITY INTEREST 27,477 23,032

NET INCOME 1,175,813 763,721

OTHER COMPREHENSIVE INCOME

Foreign currency translation adjustment 1,327,166 256,489

COMPREHENSIVE INCOME $ 2,502,979 $ 1,020,210

EARNINGS PER SHARE

Basic $ 0.08 $ 0.08

Diluted $ 0.08 $ 0.06

WEIGHTED AVERAGE SHARES OUTSTANDING

Basic 15,029,865 9,152,458

Diluted 15,339,834 12,808,226

CHINA MEDICINE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, 2008 AND DECEMBER 31, 2007

ASSETS

2008 2007

Unaudited

CURRENT ASSETS

Cash $5,177,061 $5,767,774

Accounts receivable, trade, net of'/>"/>

SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
2. China-Biotics, Inc. Completes Foundation for Its New Plant
3. Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China
4. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
5. China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results
6. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
7. DuPont Partnering with China to Increase Farm Productivity
8. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
9. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
10. Syngenta To Build Major Global Biotech Research Center in Beijing, China
11. American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... PRC Clinical, a full-service, ... Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, Israel. ... Israeli life science companies seeking to conduct U.S. Food ... span all phases of human trials, from Phase I ...
(Date:3/4/2015)... 4, 2015  BioClinica®, Inc., a leading ... today announced that clinical trial professionals representing ... its annual European User Conference in ... the use of its eClinical technologies to ... include: the Microsoft Office-Smart OnPoint CTMS; Express ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: ... diagnostics that target the underlying mechanisms of cancer, today ... ended December 31, 2014. Effective July 17, ... May 31 to December 31. As a result of ... for the quarter and the seven months ended December ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... Nov. 2, 2011 Cadence Pharmaceuticals, Inc. (NASDAQ: ... developing and commercializing proprietary products principally for use in ... and CEO Ted Schroeder will present the company,s corporate ... Time (3:30pm Eastern Time) during the Credit Suisse Healthcare ...
... 2011 Quanterix Corporation, a company enabling a ... its revolutionary Si ngle Mo lecule ... analytical performance of its Prostate Specific Antigen (PSA) ... improvement in sensitivity over today,s ultrasensitive third-generation PSA ...
... In preparation for its European launch ... 50 years, Human Genome Sciences (HGS) needed a customer ... European commercial sales team. The company had a long ... mobility, industry-specific functionality, speed, and low system maintenance. Veeva ...
Cached Biology Technology:Quanterix Fifth-Generation PSA Test Enables More Sensitive Measurements Following Surgery 2Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment 2Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment 3
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... degrees Celsius. But not salt water: Due to ... is below zero. And sea water tends to freeze ... so-called "brine channels," are formed in the ice. The ... remain in a liquid state even at lower temperatures, and ...
... satellite data, a team of scientists led by researchers from ... created a model that can successfully predict the severity and ... the rest of South America months in advance. ... the primary factor that drives the distribution of fires in ...
... rely on animals for pollination, the number of seeds they ... and the successful deposition of pollen. The number of visits ... well as on conspecific plant density. But what if a ... or has very few pollinators visiting its flowers? Will all ...
Cached Biology News:CO2 bonds in sea ice: Small living creatures with major impact 2Ocean temperatures can predict Amazon fire season severity 2Ocean temperatures can predict Amazon fire season severity 3How does a plant survive with few mates or pollinators? A European herb has figured out its own way 2How does a plant survive with few mates or pollinators? A European herb has figured out its own way 3